COX-2 inhibition in upper aerodigestive tract tumors

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cyclooxygenase-2 (COX-2) is an inducible enzyme implicated in cancer development.
• Targeting COX-2 offers a potential strategy for cancer prevention and treatment.

Purpose of the Study:

• To review the evidence for COX-2 as a pharmacological target in upper aerodigestive tract cancers.
• To discuss the role of selective COX-1 and COX-2 inhibitors in experimental and clinical settings.

Main Methods:

• Review of experimental studies on COX inhibitors in cancer models.
• Analysis of ongoing and initiated clinical trials for COX-2 inhibitors in precancerous lesions and advanced cancers.

Main Results:

• Experimental models demonstrate that selective COX-1 inhibitors reduce tumor formation and growth.
• Clinical studies are evaluating COX-2 inhibitors for chemoprevention in oral leukoplakia and Barrett's esophagus.

Conclusions:

• COX-2 represents a viable pharmacological target for upper aerodigestive tract cancers.
• Further clinical investigation is warranted to establish the efficacy of COX-2 inhibitors in cancer treatment and prevention.